

AGENDA 10-12-2019 / 9H30 TO 16H30

LOCATION

EURORDIS headquarters, 96 rue Didot 75014 Paris

Room Alesia 3 & 4. Call + 331 56 53 52 10 for assistance

PARTICIPANTS

DITA task force members

1. Vesna Aleskovska, National Alliance

2. Zsuzsa Almasi Prader willi syndrome and other rare diseases

3. Claudie Baleydier, Friedreich Ataxia

4. Janet Bloor, Duchenne musc. Dystrophy

5. Anne-Mary Bodin, Eurordis

6. Rob Camp, Eurordis

7. Tatiana Foltanova, Slovak Alliance

8. Ilaria Galetti, Scleroderma

9. François Houÿez, Eurordis

10. Diana Marinello, Behcet's syndrome association

11. Luc Matthyssen, HTAP

12. Michela Onali, GNE myopathy

13. Matteo Scarabelli, Eurordis

14. Claudia Sproedt, Cystinosis

15. Alan Timothy, rare lung diseases

16. Natacha Vaz Liti, Melanoma,

Guests

18. xxxxxxx

Excused

Isabella Brambilla. Dravet, Italy

 Danijela Szili, Rett Syndrome, Hungary

<u>Absent</u>

XXXXXXXX

Antonina Waszczuk, Sanfilippo,

Germany

· Jana Popova, neuro-

Northern Makedonia

Romania France

United Kingdom

France Spain

Slovak Rep.

Italy France Italy Belgium Italy France

Germany

United Kingdom

Portugal

17. Russel Wheeler, Leber's Hereditary Optic Neuroptic Society United Kingdom/France

muscular disorders, Bulgaria

AGEN	IDA	
1.	9h30: Welcome (François)	5'
2.	Introduction of new members	20'
3.	Possible action plan for 2019-2022 (see presentation 1)	20'
4.	Presentation of the PCWP main objectives 2019-2022	20'
	Discussion: what do you think is important to you in this work plan? See attachment	
	11h00 Coffee break	15'
5.	Repurposing – Presentation of the STAMP initiative	15'
	a. If interested: ERTC workshop 19/02/2020	
6.	Medicines Shortages - Introduction	15'
	Breakout sessions	30'
	One group works on shortages	
	- What do you need to know? What could be done?	
	One group works on drug repurposing	
	- Do you have contacts with academics who have such ideas?	
	- Do you see your role in this?	
	13:00 Lunch break	45'
7.	Report from breakout sessions	20'
8.	EMA Regulatory Science Strategy 2025 and new organisation 15'	
9.	EMA training activities for patient advocates	15'
	Breakout sessions	30'
	One group works on EMA Regulatory Science Strategy	
	One group works on EMA training activities	
10.	Report from breakout sessions	20'
11.	ICH E8 guidelines on General Considerations for Clinical	•
40	Factors	15'
	Progress report – EUROCAB programme	Rob 30'
	,	Matteo 15'
	. AOB 30 Meeting ends	10'
10.	ou meening ends	

DOCUMENTS AND BACKGROUND INFORMATION

DITA task force actions for 2019-2022 PCWP Work Plan 2019-2022 EMA Regulatory Science Strategy: see presentations

- O1- Session 1 Overview of public consultation results.pdf
- O2- Session 2 Rec.01_Support developments in precision medicine, biomarkers and omics.pdf
- O3- Session 2 Rec.02_Support translation of advanced therapy medicinal products (ATMPs) into patient treatments.pdf
- O4. Session 3a Rec.05_Create an integrated evaluation pathway for the assessment.pdf
- O5. Session 3a Rec.07_Diversify and integrate the provision of regulatory advice along the development continuum.pdf
- 🚇 06- Session 3b Rec.15-part11-16_Contribute to HTAs preparedness and downstream decision making for innovative medi...
- O7- Session 3b Rec.18_Promote use of high-quality real-world data (RWD) in decision making.pdf
- 8 08- Session 4 Rec.09_Foster innovation in clinical trials.pdf
- Ø 09- Session 4 Rec.10_Develop the regulatory framework for emerging clinical data generation.pdf
- 10- Session 4 Rec.13_Optimise capabilities in modelling, simulation and extrapolation.pdf
- 11- Session 5a Rec.17_Reinforce patient relevance in evidence generation.pdf
- 12- Session 5b Rec.28_Develop network-led partnerships with academia.pdf